A part of Watch Media

MedWatchFriday27 January 2023

  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Search
  • Log in
  • Latest
  • Search
  • Log in
  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
11/02/2022at 15:46

Leo Pharma to test tralokinumab with new device in phase III study

Although Leo Pharma’s atopic eczema treatment tralokinumab was only recently approved by the FDA 8 months behind schedule, the company is now initiating a late-stage study to investigate the drug with a new device. A syringe component was originally behind the delay.
Photo: Leo Pharma / PR
by ULRICH QUISTGAARD, translated by daniel pedersen

The US Food and Drug Administration (FDA) approved Leo Pharma’s great growth hope, tralokinumab, shortly before the New Year. Leo Pharma is now beginning to roll out the drug in the US.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters

Get full access for you and your coworkers

Start a free company trial today

Related articles:

  • Photo: Leo Pharma / PR

    Leo Pharma files for marketing approval of tralokinumab in Japan

    For subscribers

  • Photo: Leo Pharma / PR

    Leo Pharma closely followed by Pfizer and Abbvie with FDA atopic eczema approvals

    For subscribers

  • Jörg Möller, head of global research and development at Leo Pharma, doesn't have a lot to say when it comes to Leo Pharma's hopes for tralokinumab besides atopic eczema

    Leo Pharma and Astrazeneca keep future plans tight for tralokinumab

    For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.
  • AGC's Japanese and Danish factories to produce German biotech firm's drug candidate
  • AGC Biologics breaks ground on USD 190m Danish factory

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

For subscribers

Katrine Hammer (right), chief executive officer of Philips Medisize A/S in Denmark and vice president for global innovation and development in Europe | Photo: Phillips-medisize
Medtech

US medtech group expands production in Denmark

For subscribers

Per Wold-Olsen, outgoing chairman of GN's board | Foto: Mik Eskestad
Hearing health

GN's veteran chairman to retire

For subscribers

Jesper J. Lange, co-founder and CEO of MC2 Therapeutics | Photo: Mc2 Therapeutics / Pr
Pharma & biotech

MC2 Therapeutics CEO steps down as board member

For subscribers

Photo: Sebastian Kahnert/AP/Ritzau Scanpix
Pharma & biotech

Atrogi doses first patient in diabetes study

For subscribers

Further reading

Foto: Euha/foto Rechnitz
Hearing health

New batch of hearing firm recommendations moves GN up, Demant and Sonova down

Jefferies takes stock of hearing aid industry, and comes up with a new string of recommendations.

For subscribers

Per Wold-Olsen will not seek re-election as GN Group's chair in March | Photo: Mik Eskestad/Jyllands-Posten/Ritzau Scanpix
Hearing health

Per Wold-Olsen's retirement is "a great loss for GN"

An analyst reacts to the news that GN’s chair is not seeking re-election this year – ”he has been key in helping GN secure a significant position on the hearing aid market.”

For subscribers

Foto: Agc Biologics
Pharma & biotech

AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes

The contract manufacturer will produce Tzield, an approved treatment that delays the onset of stage 3 type 1 diabetes, for Provention Bio, which secured rights from Lilly’s partner in 2018.

For subscribers

Latest news

  • AGC Biologics to produce Eli Lilly-developed drug delaying type 1 diabetes – 26 Jan
  • Per Wold-Olsen's retirement is "a great loss for GN" – 26 Jan
  • US medtech group expands production in Denmark – 26 Jan
  • GN's veteran chairman to retire – 26 Jan
  • MC2 Therapeutics CEO steps down as board member – 26 Jan
  • Atrogi doses first patient in diabetes study – 26 Jan
  • FDA approves ALK's house dust mite tablet for teens – 25 Jan
  • Bavarian Nordic featured on Cowen list of 2023 biotech favorites – 25 Jan
  • Biontech inks deal with UK on sped-up cancer trials – 25 Jan
  • FDA vaccine director flagged concerns over "hyper-accelerated" review of Pfizer's Covid-19 vaccine – 25 Jan
See all

Jobs

  • Head of International Sales

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Jobs

  • Head of International Sales

  • Principal Laboratory Technologist

  • Sr. Director, Drug Safety Physician

  • Application Manager

  • Commercial Director

  • Senior Regulatory Affairs Professional

  • Lead Data Architect

  • Specialist for the supply of pharmaceuticals to Danish hospitals

  • Clinical Operational Associate

  • Two department leaders for the Department of Pharmacy and the Department of Drug Design and Pharmacology

  • Head of Regulatory Affairs Danmark

  • Application Manager

See all jobs

Colophon

MedWatch
Search

Sections

  • Pharma & biotech
  • Medtech
  • Hearing health
  • Regulation
  • Other
  • Sitemap
  • RSS feeds

Editor

Mikkel Aabenhus Hemmingsen

mah@medwatch.dk

Tel.: +45 3330 8387

Editor-in-chief

Anders Heering

Publisher

JP/Politiken Media Group Ltd

Advertising

annoncering@infowatch.dk

Tel.: +45 7077 7441

Advertising

Job Advertising

job@infowatch.dk

Tel.: +45 7077 7441

Jobs

Subscription

Try MedWatch or get an offer for a subscription meeting the exact needs of you or your company.

medwatch@infowatch.dk

Tel.: +45 7077 7441

Learn more about subscriptions here

Address

MedWatch

Rådhuspladsen 37

1785 Copenhagen K, Denmark

Tel.: +45 3330 8370

Guidelines

  • Privacy Policy

Copyright © MedWatch — All rights reserved

Microsoft is in the process of discontinuing Internet Explorer – and so are we.
For a better experience, we recommend using one of the following browsers.

Kind regards,
MedWatch

Google ChromeMozilla FirefoxMicrosoft Edge